首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Helicobacter

Helicobacter杂志,由Wiley-Blackwell Publishing Ltd出版,于1996年创刊,Quarterly,出版语言English,ISSN:1083-4389,E-ISSN:1523-5378。

投稿咨询
Helicobacter
Helicobacter
Helicobacter
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
4.6
CiteScore
8
期刊收录
SCI、SCIE

Helicobacter(中文译名:《幽门螺杆菌》),ISSN:1083-4389,EISSN:1523-5378,是Wiley-Blackwell Publishing Ltd出版的国际性学术期刊,创刊于1996年,以Quarterly形式稳定发行,2026年总发文量约77篇。该刊采用非OA开放访问,学科归属为医学 - 微生物学。该刊是医学、胃肠肝病学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4.6,2025年期刊CiteScore为8,2025年期刊自引率约6.5%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Helicobacter长期聚焦医学、胃肠肝病学及相关产业的技术应用前沿,平均审稿周期约2月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、胃肠肝病学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,South KoreaCHINA MAINLAND、Russia、Italy、France、GERMANY (FED REP GER)、USA等为核心发文国家与地区;UNIVERSITY OF LATVIACHU BORDEAUX、CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED、HOSPITAL DE LA PRINCESA、UNIVERSITE DE BORDEAUX、INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)、CATHOLIC UNIVERSITY OF THE SACRED HEART等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学 MICROBIOLOGY 微生物学
2区 2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
MICROBIOLOGY 微生物学 GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学
2区 3区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
MICROBIOLOGY 微生物学 GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学
2区 3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 38 / 153

75.5

学科:MICROBIOLOGY SCIE Q2 51 / 167

69.8

学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q2 41 / 153

73.53

学科:MICROBIOLOGY SCIE Q2 59 / 167

64.97

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 30 / 148

80.1

学科:MICROBIOLOGY SCIE Q2 45 / 163

72.7

学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 35 / 148

76.69

学科:MICROBIOLOGY SCIE Q2 52 / 163

68.4


中国学者近期发文

1
Hope Hp-GC Project-Program Implementation for Primary and Secondary Prevention of Gastric Cancer in Latin Americ

Author:Uribe, Javier; Portillo-Mino, Jose Dario; Latorre, Gonzalo; Reyes-Placencia, Diego; Pizarro, Mauricio; Vargas, Jose Ignacio; Espino, Alberto; Jure, Camila; Pizarro, Margarita; Bofill, Gabriela; Silva, Felipe; Palacios, Nilton; Diaz-Garrido, Natalia; Huidobro, Laura; Araya, Raul; Ledesma, Sergio; Otero, William; Otero, Lina; Remes-Troche, Jose M.; Campos, Christian; Largacha, Monserrate; Varas, Oscar; Cabrera, Dacio; Piscoya, Alejandro; Ramirez, Juan; Laudanno, Oscar; Esteves, Sebastian; Cifuentes, Sandra; Garcia, Eduardo; Maria-Guzman, Ana; Morgan, Douglas; Espinoza, Manuel; Shah, Shailja C.; Park, Jin Young; Camargo, M. Constanza; Riquelme, Arnoldo

Journal: HELICOBACTER. 2026; Vol. 31, Issue 2, pp. -. DOI: 10.1111/hel.70109

2
Vonoprazan Versus Tegoprazan-Amoxicillin Dual Therapy for Treatment-Naïve Patients With Helicobacter pylori Infection: A Prospective, Multicenter, Open-Label, Randomized Controlled Stud

Author:Zhou, Ya-Ni; Song, Ji-Chun; Wang, Qing-Hua; Feng, Huang; Lin, Ya; Li, De-Min; Wang, Ge; Huang, Xiao-Wei; Liu, Jing-Mei; Shen, Yan; Zhou, Xiang; Xue, Hui-Ting; Liu, Yan; Li, Pei-Yuan

Journal: HELICOBACTER. 2026; Vol. 31, Issue 2, pp. -. DOI: 10.1111/hel.70124

3
Changes of Helicobacter pylori Infection Status and Risk of Precancerous Lesions: A Prospective Cohort Study in Chinese Populatio

Author:Xing, Xufei; Zhao, Renjia; Cui, Zixuan; Xu, Qiaoyi; Yuan, Ziyu; Xu, Kelin; Zhang, Tiejun; Liu, Zhenqiu; Jiang, Yanfeng; Lu, Ming; Ye, Weimin; Suo, Chen; Chen, Xingdong

Journal: HELICOBACTER. 2026; Vol. 31, Issue 2, pp. -. DOI: 10.1111/hel.70114

4
Efficacy and Safety of Vonoprazan-Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication: A Randomized Controlled Tria

Author:Zhang, Jin-Yan; Li, Ji; Huang, Wei-Feng; Lei, Xiao-Yi; Huang, Yu-Lin; Xu, Gui-Hua; Xu, Dong

Journal: HELICOBACTER. 2026; Vol. 31, Issue 2, pp. -. DOI: 10.1111/hel.70112

5
Exosome-Based Detection of Helicobacter pylori Infection and Clarithromycin Resistance in Childre

Author:Song, Minghui; Zeng, Jingqing; Yao, Zhanyong; Xu, Chundi; Huang, Yiqiu; Xiao, Yuan; Yu, Yi; Li, Jia; Xu, Xu; Shi, Chenchen; Wu, Qiuchen; Tao, Yonglin; Tang, Xing; Ge, Gloria; Gao, Shenshen; Deng, Zhaohui; Wang, Xinqiong

Journal: HELICOBACTER. 2026; Vol. 31, Issue 2, pp. -. DOI: 10.1111/hel.70113

6
Efficacy and Safety of Keverprazan-Amoxicillin Dual Regimen in Initial Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Tria

Author:Wei, Shanshan; Huang, Zhihao; Xiong, Huizhen; Wu, Ji; Mei, Dihua; Zhao, Jing; Liu, Wei; Liu, Qingyun; Lin, Yu; Liu, Fang; Peng, Xiang; Chen, Honglei

Journal: HELICOBACTER. 2026; Vol. 31, Issue 1, pp. -. DOI: 10.1111/hel.70100

7
The Systemic Impact of Helicobacter pylori Infection on the Microbiome of Whole Digestive Tract Based on Mucosal, Gastric Juice, and Fecal Specimen

Author:Wang, Yuxin; Zhou, Kai; Zhang, Yuexi; Li, Cailing; Zhang, Yuxin; Ren, Xinlu; Mi, Changmin; Ma, Lingling; Duan, Yuqi; Liu, Mengqi; Ping, Guangjie; Tian, Xueli; Song, Zhiqiang

Journal: HELICOBACTER. 2025; Vol. 30, Issue 3, pp. -. DOI: 10.1111/hel.70047

8
Reply: Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Tria

Author:Ren, Xinlu; Song, Zhiqiang

Journal: HELICOBACTER. 2025; Vol. 30, Issue 3, pp. -. DOI: 10.1111/hel.70043

9
Authors' Reply to the Letter on Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Tria

Author:Yu, Zhengchen; Shen, Wenjuan; Lou, Guochun; Li, Yan; Xie, Ziming; Ye, Jun

Journal: HELICOBACTER. 2025; Vol. 30, Issue 3, pp. -. DOI: 10.1111/hel.70049

10
Efficacy of Three Amoxicillin Doses in Vonoprazan Dual Therapy for Helicobacter pylori Eradication: A Randomized Noninferiority Tria

Author:Peng, Ruolin; Cai, Pengpeng; Zhang, Zhimei; Lv, Shengxiang; Chen, Guangxia; Xu, Yuling; He, Bin; Sun, Min; Dai, Xiaorong; Yan, Kunfeng; Shen, Lu; Wang, Jianrong; Li, Wei; Yin, Rui; Ge, Jianxin; Hu, Duanmin; Hu, Kewei; Xu, Xiaodan; Li, Hui; Pan, Chengyu; Duan, Zhaotao; Gao, Xuefeng; Zhang, Zhenyu; Liu, Wanli

Journal: HELICOBACTER. 2025; Vol. 30, Issue 3, pp. -. DOI: 10.1111/hel.70050


在线咨询

Helicobacter

国际简称:HELICOBACTER参考译名:幽门螺杆菌

年发文量:77 CiteScore:8 是否预警:否 Gold OA文章占比:27.04% 研究类文章占比:83.12%

杂志社联系方式:WILEY-BLACKWELL PUBLISHING, INC, COMMERCE PLACE, 350 MAIN ST, MALDEN, USA, MA, 02148

Helicobacter